Page 6,635«..1020..6,6346,6356,6366,637..6,6406,650..»

Research and Markets: Annals Meeting Reports – Diabetes and Oral Disease, Stem Cells, and Chronic Inflammatory Pain

Posted: Published on August 1st, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/lpl7vb/annals_meeting_rep) has announced the addition of John Wiley and Sons Ltd's new book "Annals Meeting Reports. Diabetes and Oral Disease, Stem Cells, and Chronic Inflammatory Pain" to their offering. This volume presents reports from recent scientific meetings on topics in emerging fields: (1) Diabetes and Oral Disease: Implications for Health Professionals; (2) The New York Stem Cell Foundation: Sixth Annual Translational Stem Cell Research Conference; and (3) Chronic Inflammatory and Neuropathic Pain. "Diabetes and Oral Disease: Implications for Health Professionals" was a one-day conference convened by the Columbia University College of Dental Medicine, the Columbia University College of Physicians and Surgeons, and the New York Academy of Sciences on May 4, 2011 at The New York Academy of Sciences in New York City. The program included an examination of the bidirectional relationship between oral disease and diabetes and the inter-professional working relationships for the care of people who have diabetes. The overall goal of the conference was to promote discussion among the healthcare professions who treat people with diabetes, encourage improved communication and collaboration among them and ultimately, improve patient management of the oral and overall effects of diabetes. Attracting over 150 members of the … Continue reading

Posted in Stem Cell Research | Comments Off on Research and Markets: Annals Meeting Reports – Diabetes and Oral Disease, Stem Cells, and Chronic Inflammatory Pain

Lame dogs brought to heal with stem cells Save

Posted: Published on August 1st, 2012

July 29, 2012, 3 a.m. Up for a walk ... Denise Stuckey, with her dog, Bella, who has had stem cell treatment from vet Joe Sulyok. Stem cell injections in dogs will become routine in the next two years and will probably cost less than $1000. The first data, collated last week, into the use of the procedure where cultured cells are injected into the joints of dogs with hip dysplasia or canine osteoarthritis has shown a success rate of 96 per cent. The procedure will be made available to veterinary clinics, promoted at dog shows and possibly in a television campaign. It has been transformed in little more than a year with stem cells from one animal used to treat other dogs. Previously, an invasive procedure was necessary, with incisions to remove subcutaneous or fatty tissue from the affected dog and stem cells isolated in a laboratory before being injected back into the dog. The procedure resulted in a culture containing only about 10 per cent to 15 per cent stem cells, while the culture from a donor in a breed with a genetic line clear of arthritis can been screened to provide a culture containing 100 per cent … Continue reading

Posted in Stem Cell Research | Comments Off on Lame dogs brought to heal with stem cells Save

Genetic disorder means daily battle with calculated risks

Posted: Published on August 1st, 2012

By MEGAN GRAHAM In his old room in his parents' home, a pretty house in the Cherry Hills subdivision of Champaign, Chike Coleman is poking through his shelves. He wants to find a Blu-ray disc, one of the beloved movies he bought in a half-off online sale from a site that sells independent films. He moves aside tens of his prized jazz CDs, the Soapbox Derby trophies and the Hardy Boys books. The shelves are filled with 25 years of memories: books he has loved, model cars done in candy-colored lacquer, his University of Illinois diploma. His high school and college friends most 25-year-olds, for that matter no longer live in the dust of their boyhood belongings. But after his fleeting years of collegiate freedom, Chike moved right back into this room, with its boxes of waterproof dressing and nonstick pads and bandages, bottles of hydrogen peroxide, soap-free cleanser and Clindamycin gel. "It's just kind of waiting," he says. "Just like everybody else. Except your wait feels a lot shorter than everybody else's." Chike glances at a photograph of him leaning back casually in his wheelchair, royal blue graduation gown draping his chest as he smiles broadly. He looks normal. … Continue reading

Comments Off on Genetic disorder means daily battle with calculated risks

Ashkenazi Jewish Genetic Disease Carrier Screening Now More Affordable in the New York Metropolitan Area

Posted: Published on August 1st, 2012

The Program for Jewish Genetic Health of Yeshiva University / Einstein is offering accessible and affordable carrier screening for Jewish genetic diseases. New York, New York (PRWEB) August 01, 2012 The Program for Jewish Genetic Health (PJGH) of Yeshiva University/Einstein has announced that it has enabled the most affordable and comprehensive Ashkenazi Jewish genetic disease carrier screening to date in the New York metropolitan area. Carrier screening via the PJGH, which includes individual genetic counseling sessions for each participant, is offered through the clinical services of the Division of Reproductive Genetics of Montefiore Medical Center/Einstein. The PJGH advocates that individuals and couples undergo genetic screening prior to conception; many health insurance policies, however, will provide only partial coverage at that stage. To address this issue, the PJGH, with assistance from its philanthropic and laboratory partners, has been facilitating low-cost screening for both uninsured and underinsured patients for several years. Thanks to a new relationship with leading genetic testing company Counsyl, who only recently received accreditation from the New York State Department of Health for the testing of New York State residents, the PJGH is able to further lower the cost of screening for all individuals. We are thrilled to be … Continue reading

Comments Off on Ashkenazi Jewish Genetic Disease Carrier Screening Now More Affordable in the New York Metropolitan Area

23andMe Genetic Testing Company Applies For FDA Approval

Posted: Published on August 1st, 2012

August 1, 2012 Connie K. Ho for redOrbit.com Your Universe Online 23andMe, a company focused on personal genetics, recently took the first step in working towards Food and Drug Administration (FDA) clearance; the FDA plans to review the paperwork over the next few months. Previously, the Silicon Valley company refrained from government regulation, claiming that the service provided consumers with information rather than a medical service. CBS News reported that 23andMe submitted the first group of seven health-related tests for the FDA to review. By the end of next year, the organization will have submitted another 100 tests to the agency. With these exams, the organization hopes to obtain government approval and scientific credibility. 23andMe has pioneered the direct-to-consumer genetic testing industry and we are committed to helping individuals understand their own genetic information through proven DNA analysis technologies and web-based interactive tools, commented Anne Wojcicki, 23andMe CEO and Co-Founder, in a prepared statement. 23andMe is working proactively with the FDA to ensure the industry delivers high quality information that consumers can trust. 23andMes Personal Genome Service allows individuals to learn more about their personal DNA, offering over 200 health and trait reports along with information on genetic ancestry. The … Continue reading

Comments Off on 23andMe Genetic Testing Company Applies For FDA Approval

Stem Cell Therapy Only Works With Younger Hearts

Posted: Published on August 1st, 2012

Editor's Choice Main Category: Stem Cell Research Also Included In: Biology / Biochemistry Article Date: 31 Jul 2012 - 14:00 PDT Current ratings for: Stem Cell Therapy Only Works With Younger Hearts The researchers, using mice as their subjects, came to the conclusion that undifferentiated precursor cells grow new heart cells in a two-day-old mouse, but not in adult mice. This finding settled a decades-old debate whether or not stem cells can play a role in the recovery of the adult mammalian heart after infarction (when heart tissue dies due to a local lack of oxygen). Stem cells are biological cells found in all multicellular organisms. They are characterized by the ability to divide through mitosis and differentiate into diverse specialized cell types. They can self-renew to produce more stem cells. Michael Kotlikoff, dean of Cornell's College of Veterinary Medicine and senior author of the paper that will appear August 29th in the Proceedings of the National Academy of Sciences, said: According to Kotlikoff and team, the two-day old mice were able to grow new heart cells and almost completely recover from infarction, which proved that the injury did not stop stem cells from growing new heart cells. The results … Continue reading

Comments Off on Stem Cell Therapy Only Works With Younger Hearts

Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of Pacritinib Phase 3 Trial; Reports Second …

Posted: Published on August 1st, 2012

SEATTLE, Aug. 1, 2012 /PRNewswire/ --Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the second quarter of 2012. Recent Company Highlights "Based on in-market research among more than 250 lymphoma specialists in the five major market countries in the European Union ("EU"), we are encouraged by the interest and potential adoption of Pixuvri for treatment," stated James A. Bianco, M.D., President and CEO of CTI. "We believe we can present an argument for Pixuvri to provide fair pricing reimbursement in an effort to address the commercial potential of Pixuvri in the E.U. On the heels of our projected fourth quarter launch of Pixuvri in the E.U., we expect to start pivotal studies of our recent JAK2 product acquisition, pacritinib. In the meantime, we are also advancing tosedostat toward its phase 3 clinical trial." Financial Results For the quarter endedJune 30, 2012, total operating expenses were$49.4 millioncompared to$16.9 millionfor the same period in 2011. The increase is predominantly due to an acquired in-process research and development expense of $29.1 million relating primarily to the acquisition of pacritinib from S*BIO Pte Ltd. ("S*BIO"), in addition to equity-based compensation and expenses related … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of Pacritinib Phase 3 Trial; Reports Second …

Lame dogs brought to heal with stem cells Save

Posted: Published on August 1st, 2012

July 29, 2012, 3 a.m. Up for a walk ... Denise Stuckey, with her dog, Bella, who has had stem cell treatment from vet Joe Sulyok. Stem cell injections in dogs will become routine in the next two years and will probably cost less than $1000. The first data, collated last week, into the use of the procedure where cultured cells are injected into the joints of dogs with hip dysplasia or canine osteoarthritis has shown a success rate of 96 per cent. The procedure will be made available to veterinary clinics, promoted at dog shows and possibly in a television campaign. It has been transformed in little more than a year with stem cells from one animal used to treat other dogs. Previously, an invasive procedure was necessary, with incisions to remove subcutaneous or fatty tissue from the affected dog and stem cells isolated in a laboratory before being injected back into the dog. The procedure resulted in a culture containing only about 10 per cent to 15 per cent stem cells, while the culture from a donor in a breed with a genetic line clear of arthritis can been screened to provide a culture containing 100 per cent … Continue reading

Comments Off on Lame dogs brought to heal with stem cells Save

Removing kidney increases risk of erectile dysfunction

Posted: Published on July 31st, 2012

Removal of a kidney can greatly increase the risk of erectile dysfunction. (National Library of Medicine / National Institutes of Health) July 31, 2012, 11:43 a.m. Total removal of a kidney during cancer treatment increases the risk of developing erectile dysfunction nearly four-fold compared with patients who have only a partial removal, researchers reported Tuesday. In light of other research, which shows that partial removal (known as partial nephrectomy) is at least as effective and probably more effective than complete removal (radical nephrectomy), it now seems reasonable that radical nephrectomy should be reserved as a last resort. Dr. Ithaar Derweesh, a urologic surgeon at the UC San Diego Health System, and his colleagues studied 264 patients who underwent a radical nephrectomy and 168 who underwent a partial nephrectomy at either the UC San Diego Medical Center or the University of Tennessee Health Science Center in Memphis between January 1988 and December 2007. The team assessed the patients' sexual health and activity before the surgery and at least six months afterward. The researchers reported in the British Journal of Urology International that the patients who had radical nephrectomies had larger tumors and were more likely to have erectile dysfunction before cancer … Continue reading

Posted in Erectile Dysfunction | Comments Off on Removing kidney increases risk of erectile dysfunction

FDA Approves Qsymia Diet Drug, with Warnings About Side Effects

Posted: Published on July 31st, 2012

Posted by Eric ChaffinJuly 31, 2012 9:45 AM Most of us know that our country is in the grips of an obesity epidemic. Doctor recommended diet and exercise programs have not controlled the problem, so pharmaceutical companies are hard at work coming up with other solutions. Last month, the FDA approved Belviq (lorcaserin) as a weight-loss drug for those with a body mass index (BMI) of 30 or greater. More recently, the FDA approved Qsymia (phentermine and topiramate extended-release) for chronic weight management in addition to a reduced-calorie diet and exercise. These drugs come with potentially serious side effects, and it seems like once again the public is taking part in a giant experiment. For example, federal officials are requiring post-marketing studies to look for evidence of increased heart disease or stroke risk in those who take Qsymia. Concerns About Cardiovascular Risks It was only about a year-and-a-half ago that the FDA rejected manufacturer Vivus first petition to approve Qsymia (pronounced kyoo sim EE uh). Among other things, the agency was concerned that the drug could increase the risk of heart attack and stroke. The FDA rejected Belviq in an earlier request for approval because of similar concerns. Experts believe … Continue reading

Posted in Drug Side Effects | Comments Off on FDA Approves Qsymia Diet Drug, with Warnings About Side Effects

Page 6,635«..1020..6,6346,6356,6366,637..6,6406,650..»